ImCheck Therapeutics Company
.jpg)
ImCheck Therapeutics is a developing novel therapeutics that target members of the butyrophilin (BTN) super-family of checkpoint molecules.
Total Funding:
$78 381 002
Headquarters:
Marseille, Provence-Alpes-Cote d'Azur, France
Funding Status:
Early Stage Venture
Estimated Revenue:
Less than $1M
Last Funding Type:
Series B
Last Funding Date:
2019-12-04
Founded Date:
2015-01-01
Industry:
Women Cancer Treatment